NCT04800237: A trial that was reported late by Vanda Pharmaceuticals
This trial has reported, although it was 234 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04800237 |
|---|---|
| Title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of VQW-765 in Patients With Performance Anxiety |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 23, 2021 |
| Completion date | Aug. 2, 2022 |
| Required reporting date | Aug. 2, 2023, midnight |
| Actual reporting date | March 23, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 18, 2025 |
| Days late | 234 |